Mycotic Research

Click the links below to find more information:


Jingle Bell JogZippity Doo Dah gives to BCHJackson Free ClinicCommencement 2014
  • Publications

    • Levitz SM, Shoham S, Cleary JD. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008;359(17):1766-77 comment.
    • Stover K, Cleary JD. Antifungal Drugs. In: Clinical Drug Data 11th edition. McGraw Hill, Inc, 2009
    • Cleary JD, Pearson M, Oliver J, Chapman SW. Association between Histoplasma exposure and stroke. J Stroke Cerebrovasc Dis 2008;17(5):312-9.
    • Cleary JD, Chapman SW, Pearson MM. Antimycotic Pharmacotherapy. In: Koda-Kimble MA & Young LY, eds. Applied Therapeutics Eighth Edition. Vancouver: Applied Therapeutics, Inc, 2008.
    • Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother 2008;52(6):2263-5.
    • Sealy PI, Garner B, Swiatlo E, Chapman SW, Cleary JD. The interaction of mannose binding lectin (MBL) with mannose containing glycopeptides and the resultant potential impact on invasive fungal infection. Med Mycol 2008.
    • Chapman SW, Sullivan DC, Cleary JD. In search of the holy grail of antifungal therapy. Trans Am Clin Climatol Assoc 2008;119:197-216.
    • Cleary JD, Chapman SW, Swiatlo E, Kramer R . High Purity Amphotericin B. J Antimicrob Chemother 2007;60(6):1331-40.
    • Cleary JD, Graham D, Lushbaugh WB, Nolan RL, Chapman SW. Single low-dose mebendazole administered quarterly for ascaris treatment. Am J Med Sci. 2007;333(6):340-5.
    • Ross LA, Crabtree BL, Theilman GD, Cleary JD, Byrd HJ. Implementation of Problem Based Learning: 10 Years Later. Am J Pharm Ed 2007; 71(1): 1-14.
    • Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P, Benjamin D, Rubin R, Aberg JA, Adderson EE, Adler-Shohet FC, Akan H, Akova M, Almyroudis NG, Alexander BD, Andes D, Arrieta A, Baddley JW, Barron MA, Belzberg H, Boucher HW, Boyce TG, Casadevall A, Chandrasekar PH, Cleary JD, Cordonnier C, Cornely OA, Cuenca-Estrella M, Daly JS, Daoura N, Denning DW, dePauw B, de Repentigny L, Dignani MC, Dismukes WE, Donnelly JP, Donowitz GR, Dupont B, Drusano G, Ellis M, Espinel-Ingroff A, Fishman JA, Fleming R, Forrest G, Ghannoum M, Goldman M, Grazziutti M, Greene JN, Greenberg RN, Gubbins PO, Hadley S, Herbrecht R, Hiemenz JW, Hope W, Hospenthal DR, Husain S, Ito JI, Jacobson RM, Johnson M, Keating MR, Kett DH, Knapp K, Kontoyiannis DP, Krcmery VC, Larsen R, Laverdiere M, Ljungman P, Lortholary O, Maertens J, Marriott D, Mattiuzzi G, McGinnis MR, Morris M, Nucci M, Odds FC, Pankey GA, Patterson T, Pfaller M, Razonable RR, Reboli AC, Rinaldi MG, Roberts GD, Rodriguez Tudela JL, Rotstein C, Ruhnke M, Schuster M, Shoham S, Sia IG, Siebel N, Silviera F, Singh N, Sobel J, Solomkin JS, Sorrell TC, Steinbach WJ, Temesgen Z, Tortorano A, Vartivarian S, VerWeij P, Viscoli C, Viviani MA, Walker RC, Wheat JL, Wiley J, Williamson P, Wingard JR, Yu VL, Zaoutis T. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. Clin Infect Dis. 2006;43(8):1031-9.
    • Cleary JD, Walker LA, Hawke RL. Antimycotic Discovery in the Age of Genomics. Am J Pharmacogenomics 2005, 5(6):1-22
    • Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, Schlamm HT, Oborska IT, Hilton F, Hodges MR. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomized non-inferiority trial. Lancet 2005;366(9495):1435-42.
    • Saathoff AD, Elkins SL, Chapman SW, McAllister SF, Cleary JD. Thrombocytosis during antifungal therapy of candidemia. Ann Pharmacother 2005;39(7-8):1238-43.
    • Glisson J, Wood RL, Kyle PB, Cleary JD. Bioavailability of promethazine in a topical pluronic lecithin organogel: A pilot study. International Journal of Pharmaceutical Compounding 2005; 9(3): 242-6.
    • Cleary JD, Chapman SW, Pearson MM. Antimycotic Pharmacotherapy. In: Koda-Kimble MA & Young LY, eds. Applied Therapeutics Seventh Edition. Vancouver: Applied Therapeutics, Inc, 2005.
    • Cleary JD, Rogers PD, Chapman SW. Variability in polyene content and cellular toxicity among deoxycholate amphotericin B formulations. Pharmacotherapy 2003;23(5):572-8.
    • Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47 (10): 3149-54.
    • Cleary JD, Schwartz M, Rogers PD, de Mestral J, Chapman SW. Effects of amphotericin B and caspofungin on histamine expression. Pharmacotherapy. 2003;23(8):966-73.
    • Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE, et al. A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-43.
    • Agarwal AK, Rogers PD, Baerson SR, Jacob MR, Barker KS, Cleary JD, Walker LA, Nagle DG, Clark AM Genome-wide Expression Profiling of the Response to Polyene, Pyrimidine, Azole, and Echinocandin Antifungal Agents in Saccharomyces cerevisiae J. Biol. Chem. 2003 278: 34998-35015.
    • Cleary JD, Rogers PD, Chapman SW. Variability in polyene content and cellular toxicity among deoxycholate amphotericin B formulations. Pharmacotherapy 2003; 23(5):572-8.
    • Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz HW, Zervos M, McKinsey D, Lee J, Babinchak T, Bradsher RW, Cleary JD, Cohen DM, Danziger L, Goldman M, Goodman J, Hilton E, Hyslop NE, Kett DH, Lutz J, Rubin RH, Scheld WM, Schuster M, Simmons B, Stein DK, Washburn RG, Mautner L, Chu TC, Panzer H, Rosenstein RB, Booth J. A Randomized and Blinded Multicenter Trial of High-Dose Fluconazole plus Placebo versus Fluconazole plus Amphotericin B as Therapy for Candidemia and Its Consequences in Nonneutropenic Subjects. Clin Infect Dis 2003;36(10):1221-8.
    • Pearson MM, Rogers PD, Cleary JD, Chapman SW. Voriconazole, a new triazole antifungal agent. Journal of Antimicrobial Chemotherapy. Annals Pharmacother 2003; 37(3): 420-32.
    • Cleary JD. Atypical TB Skin Test Reaction. Annals Pharmacother 2003; 37(3): 451.
    • Shain CS, Cleary JD. Buffalo hump in an HIV-infected patient. Annals of Pharmacotherapy 2002; 36:1807.
    • Rogers PD, Pearson MM, Cleary JD, Chapman SW, Sullivan DC. Differential expression of genes encoding immunomodulatory proteins in response to amphotericin B in the human monocytic cell line THP-1 identified by cDNA array analysis. J Antimicrob Chemother. 2002;50(6):811-7.
    • Local atrophy following steroid injection. Cleary JD. Annals of Pharmacotherapy 2002; 36: 726.
    • Blossom AP, Cleary JD, Daley WP. Acyclovir-Induced Crystalluria. Annals of Pharmacotherapy 2002; 36: 526.
    • Clinkscales A, Cleary JD. Steroid-Induced Avascular Necrosis. Ann Pharmacother 2002; 36(6): 1105.
    • Slain D, Rogers PD, Chapman SW, Cleary JD. Intravenous Itraconazole: A Formulary Focus. Ann Pharmacotherapy 2001; 35: 720-9.
    • Cleary JD. Wheezer: A five-session problem-based learning case focusing on community acquired pneumonia for fifth-year doctor of pharmacy students. The Journal Clinical Problem-based Learning 2001; Fall(5).